Shalvata Mental Health Center

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

2 marketed ·

Quick facts

Marketed products

Ketamine (1st phase) · Psychiatry / Mental Health
Ketamine is a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor that blocks glutamate signaling in the brain.
Ketamine (2st phase) · Psychiatry, Anesthesia, Pain Management
Ketamine is a non-competitive NMDA receptor antagonist that blocks glutamate signaling in the brain, producing rapid-onset dissociative anesthesia and analgesic effects.

Phase 2 pipeline

Hair Sample

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Frequently asked questions about Shalvata Mental Health Center

What are Shalvata Mental Health Center's marketed drugs?

Top marketed products include Ketamine (1st phase), Ketamine (2st phase).

Ketamine (1st phase) · Psychiatry / Mental Health
Ketamine (2st phase) · Psychiatry, Anesthesia, Pain Management
Sector hub: All tracked pharma companies